<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="808">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00184665</nctid>
  <trial_identification>
    <studytitle>Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes</studytitle>
    <scientifictitle>2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN304-1595</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - insulin detemir
Treatment: drugs - insulin NPH
Treatment: drugs - insulin aspart

Treatment: drugs: insulin detemir


Treatment: drugs: insulin NPH


Treatment: drugs: insulin aspart


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c</outcome>
      <timepoint>after a two-year trial period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body weight</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antibodies</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypoglycaemia</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 1 diabetes

          -  Currently on basal-bolus regimen

          -  BMI = 35.0 kg/m2

          -  HbA1c =11.0%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Proliferative retinopathy or maculopathy

          -  Recurrent major hypoglycaemia

          -  Cardial problems

          -  Uncontrolled hypertension

          -  Impaired hepatic or renal function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>501</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,TAS,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - St Leonards</hospital>
    <hospital>Novo Nordisk Investigational Site - Hobart</hospital>
    <hospital>Novo Nordisk Investigational Site - Melbourne</hospital>
    <hospital>Novo Nordisk Investigational Site - Darlinghurst</hospital>
    <hospital>Novo Nordisk Investigational Site - Stones Corner</hospital>
    <hospital>Novo Nordisk Investigational Site - Woodville</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>4120 - Stones Corner</postcode>
    <postcode>5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma de Bs As</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Aut√≥noma de BsAs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mar del Plata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <state>Skopje</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Cheras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu, Kelantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bornova-IZMIR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this
      research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of
      insulin detemir compared to NPH insulin administered as basal insulin for the treatment of
      type 1 diabetes and to verify the safety of use (number and severity of episodes of
      hypoglycemia, body weight, and insulin antibodies and side effects).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00184665</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>